EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors that act against the epidermal growth factor receptor (EGFR-TKIs) have shown clinical benefit against NSCLC involving EGFR mutations (Mok et al., 2009; Wu et al., 2014).